Drug Information

Drug General Information
Drug ID
D0B4XX
Former ID
DIB003908
Drug Name
QR-333
Indication Diabetic neuropathy [ICD9: 250, 250.6, 356.0, 356.8; ICD10:E11.40] Phase 2 [522174]
Company
Quigley Pharma Inc
Target and Pathway
Target(s) Aldose reductase Target Info Inhibitor [527695]
BioCyc Pathway Methylglyoxal degradation III
Acetone degradation I (to methylglyoxal)
KEGG Pathway Pentose and glucuronate interconversions
Fructose and mannose metabolism
Galactose metabolism
Glycerolipid metabolism
Metabolic pathways
NetPath Pathway IL1 Signaling Pathway
TGF_beta_Receptor Signaling Pathway
PathWhiz Pathway Fructose and Mannose Degradation
Pyruvate Metabolism
Pterine Biosynthesis
Glycerolipid Metabolism
Galactose Metabolism
WikiPathways Metapathway biotransformation
Polyol Pathway
Metabolism of steroid hormones and vitamin D
References
Ref 522174ClinicalTrials.gov (NCT00568035) Safety and Efficacy Study of QR-333 in Patient's With Symptomatic Diabetic Neuropathy. U.S. National Institutes of Health.
Ref 527695A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report. J Diabetes Complications. 2005 Sep-Oct;19(5):247-53.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.